Role of Angiopoietins and Tie-2 in Diabetic Retinopathy
Keywords:
Angiopoietins, Tie-2 receptor, Diabetic RetinopathyAbstract
Objective: The aim of this study was to determine the serum levels of angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2), soluble vascular endothelial tyrosine kinase receptor (Tie-2) and vascular endothelial growth factor (VEGF), in the serum of type 2 diabetic patients having non-proliferative (NPDR) or proliferative diabetic retinopathy (PDR).
Methods: One hundred patients with type 2 diabetes mellitus were involved in this cross-sectional study. They were classified into 25 diabetic patients without retinopathy, 35 patients with NPDR and 40 PDR patients. The study was carried out in the outpatients clinic of the Research Institute of Ophthalmology, Giza, Egypt from August 2016 through May 2017. Serum VEGF, Ang-1, Ang-2 and Tie-2 receptor levels were assayed using enzyme linked immunosorbent assay (ELISA). Data were analyzed by SPSS version 20 and Microsoft Excel (Version 10) using ANOVA, Harman's single factor test, and Pearson’s Product Moment Correlation.
Results: The serum levels of Ang-2 and VEGF were significantly elevated in NPDR groups and PDR group compared to diabetics without retinopathy groups (p<0.001). The serum levels of Ang-1 were significantly higher in the NPDR group compared to the diabetics without retinopathy groups (p<0.01), while no significant difference was observed between the PDR and diabetics without retinopathy groups. Ang-1/Ang-2 ratio was the lowest in the PDR group compared to the NPDR and diabetics without retinopathy groups. The serum levels of Tie-2 were not significantly changed among the three studied groups, serum Ang-2 was positively correlated with VEGF and Tie-2 in the PDR and NPDR groups.
Conclusion: The angiopoietin /Tie system and VEGF are essential features in the commencement and development of PDR.
References
Yau JW1, Rogers SL, Kawasaki R; Meta-Analysis for Eye Disease (META-EYE) Study Group. Global
prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012 Mar;35(3):556-64. doi:
2337/dc11-1909, PMid: 22301125, PMCid: PMC3322721
Campochiaro PA. Molecular pathogenesis of retinal and choroidal vascular diseases. Prog Retin Eye Res.
Nov;49:67-81. doi: 10.1016/j.preteyeres.2015.06.002, PMid: 26113211, PMCid: PMC4651818
Campochiaro PA, Aiello LP, Rosenfeld PJ. Anti-Vascular Endothelial Growth Factor Agents in the
Treatment of Retinal Disease: From Bench to Bedside. Ophthalmology. 2016 Oct;123(10S):S78-S88. doi:
1016/j.ophtha.2016.04.056, PMid: 27664289
Kinnunen K, YLa-Herttuala S. Vascular endothelial growth factors in retinal and choroidal neovascular
diseases. Ann Med. 2012 Feb;44(1):1-17. doi: 10.3109/07853890.2010.532150, PMid: 21284527
Feraud O, Mallet C, Vilgrain I. Expressional regulation of the angiopoietin-1 and -2 and the endothelial- specific receptor tyrosine kinase Tie2 in adrenal atrophy: a study of adrenocorticotropin-induced repair.
Endocrinology. 2003 Oct;144(10):4607-15. doi: 10.1210/en.2003-0099, PMid: 12960064
Brkovic A, Pelletier M, Girard D, Sirois MG. Angipoietin chemotactic activities on neutrophils are
regulated by PI-3K activation. J Leukoc Biol. 2007 Apr;81(4):1093-101. doi: 10.1189/jlb.0906580, PMid:
Eklund L, Saharinen P. Angiopoietin signaling in the vasculature. Exp Cell Res. 2013 May
;319(9):1271-80. doi: 10.1016/j.yexcr.2013.03.011, PMid: 23500414
Joussen AM, Poulaki V, Tsujikawa A, Qin W, Qaum T, Xu Q, Moromizato Y, Bursell SE, Wiegand SJ,
Rudge J, Ioffe E, Yancopoulos. GD, Adamis AP. Suppression of diabetic retinopathy with angiopoietin-1.
Am J Pathol. 2002 May;160(5):1683-93. doi: 10.1016/S0002-9440(10)61115-7
Nambu H, Nambu R, Oshima Y, Hackett SF, Okoye G, Wiegand S, Yancopoulos G, Zack DJ,
Campochiaro PA. Angiopoietin 1 inhibits ocular neovascularization and breakdown of the blood-retinal
barrier. Gene Ther. 2004 May;11(10):865-73. doi: 10.1038/sj.gt.3302230, PMid: 15042118
Felcht M, Luck R, Schering A, Seidel P, Srivastava K, Hu J, Bartol A, et al. Angiopoietin-2 differentially
regulates angiogenesis through TIE2 and integrin signaling. J Clin Invest. 2012 Jun;122(6):1991-2005. doi:
1172/JCI58832, PMid: 22585576, PMCid: PMC3366398
Sarlos S, Rizkalla B, Moravski CJ, Cao Z, Cooper ME, Wilkinson-Berka JL. Retinal angiogenesis is
mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin. Am J Pathol.
Sep;163(3):879-87. doi: 10.1016/S0002-9440(10)63448-7.
Peters S, Cree IA, Alexander R, Turowski P, Ockrim Z, Patel J, et al. Angiopoietin modulation of vascular
endothelial growth factor: Effects on retinal endothelial cell permeability. Cytokine. 2007 Nov;40(2):144- 50. doi: 10.1016/j.cyto.2007.09.001, PMid: 17959386
Watanabe D, Suzuma K, Suzuma I, Ohashi H, Ojima T, Kurimoto M, et al. Vitreous Levels of angiopoietin
and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am J
Ophthalmol. 2005 Mar;139(3):476-81. doi: 10.1016/j.ajo.2004.10.004, PMid: 15767056
Hackett SF, Ozaki H, Strauss RW, Wahlin K, Suri C, Maisonpierre P, et al. Angiopoietin 2 expression in
the retina: upregulation during physiologic and pathologic neovascularization. J Cell Physiol. 2000
Sep;184(3):275-84. doi: 10.1002/1097-4652(200009)184:3<275::AID-JCP1>3.0.CO;2-7
Patel JI, Hykin PG ,Gregor ZJ, Boulton M, Cree IA. Angiopoietin concentrations in diabetic retinopathy.
Br J Ophthalmol. 2005 Apr;89(4):480-3. doi: 10.1136/bjo.2004.049940, PMid: 15774928, PMCid:
PMC1772595
Cai J, Kehoe O, Smith GM, Hykin P, Boulton ME. The angiopoietin/Tie-2 system regulates pericyte
survival and recruitment in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2008 May;49(5):2163-71. doi:
1167/iovs.07-1206, PMid: 18436850
Pfister F, Wang Y, Schreiter K, vom Hagen F, Altvater K, Hoffmann S, et al. Retinal overexpression of
angiopoietin-2 mimics diabetic retinopathy and enhances vascular damages in hyperglycemia. Acta
Diabetol. 2010 Mar;47(1):59-64. doi: 10.1007/s00592-009-0099-2, PMid: 19238311
Mandriota SJ, Pepper MS. Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial
cells by cytokines and hypoxia. Circ Res. 1998 Oct 19;83(8):852-9. doi: 10.1161/01.RES.83.8.852, PMid:
Oh H, Takagi H, Suzuma K, Otani A, Matsumura M, Honda Y. Hypoxia and vascular endothelial growth
factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells. J Biol Chem. 1999
May 28;274(22):15732-9. doi: 10.1074/jbc.274.22.15732, PMid: 10336473
Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, et al. Vessel cooption,
regression, and growth in tumors mediated by angiopoietins and VEGF. Science, 1999 Jun
;284(5422):1994-8. doi: 10.1126/science.284.5422.1994, PMid: 10373119
Hammes HP, Feng Y, Pfister F, Brownlee M. Diabetic retinopathy: targeting vasoregression. 2011;60(1):9- 16
Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G, et al. Angiopoietin-2 sensitizes
endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med. 2006
Feb;12(2):235-9. doi: 10.1038/nm1351, PMid: 16462802
Hang H, Bhat A, Woodnutt G, Lappe R. Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev
Cancer. 2010 Aug;10(8):575-85. doi: 10.1038/nrc2894, PMid: 20651738
Gardizi M, Kurschat C, Riese A, Hahn M, Krieg T, Mauch C, Kurschat P. A decreased ratio between
serum levels of the antagonistic angiopoietins 1 and 2 indicates tumour progression of malignant
melanoma. Arch Dermatol Res. 2012 Jul;304(5):397-400. doi: 10.1007/s00403-012-1228-2, PMid:
Lip PL, Belgore F, Blann AD, Hope-Ross MW, Gibson JM, Lip GY. Plasma VEGF and soluble VEGF
receptor Flt-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment.
Invest Ophthalmol Vis Sci. 2000 Jul;41(8):2115-9. PMid: 10892852
Mahdy RA, Nada WM. Evaluation of the role of vascular endothelial growth factor in diabetic retinopathy.
Ophthalmic Res. 2011;45(2):87-91. doi: 10.1159/000317062, PMid: 20720438
Lip P L, Chatterjee S, Caine G J. Hope-Ross M, Gibson J, Blann AD, Lip GY. Plasma vascular endothelial
growth factor, angiopoietin-2, and soluble angiopoietin receptor tie-2 in diabetic retinopathy: effects of
laser photocoagulation and angiotensin receptor blockade. Br J Ophthalmol. 2004 Dec;88(12):1543-6. doi:
1136/bjo.2004.048587, PMid: 15548809, PMCid: PMC1772428
Qiao-Ying You,Fu-Yuan Zhuge,Qi-Qian Zhu and Xu-Wei Si, Effects of laser photocoagulation on serum
angiopoietin-1, angiopoietin-2, angiopoietin-1/angiopoietin-2 ratio, and soluble angiopoietin receptor Tie-2
levels in type 2 diabetic patients with proliferative diabetic retinopathy. Int J Ophthalmol. 2014; 7(4): 648–
PMid: 25161936, PMCid: PMC4137200
Campochiaro PA and Peters KG. Targeting Tie2 for Treatment of Diabetic Retinopathy and Diabetic
Macular Edema. Curr Diab Rep. Curr Diab Rep. 2016 Dec;16(12):126. doi: 10.1007/s11892-016-0816-5,
PMid: 27778249
Moss A. The Angiopoietin: Tie 2 Interaction: A Potential Target for Future Therapies in Human Vascular
Disease. Cytokine Growth Factor Rev. 2013 Dec;24(6):579-92. doi: 10.1016/j.cytogfr.2013.05.009, PMid:
Gnudi L. Angiopoietins and diabetic nephropathy. Diabetologia. 2016 Aug;59(8):1616-20. doi:
1007/s00125-016-3995-3, PMid: 27207083, PMCid: PMC4930459
Published
Issue
Section
License
Copyright (c) 2020 KNOWLEDGE KINGDOM PUBLISHING
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
